trending Market Intelligence /marketintelligence/en/news-insights/trending/aulmkh1jhqgvzmiepghyng2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

AngioSoma acquiring Diabetes Relief to facilitate development of artery drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


AngioSoma acquiring Diabetes Relief to facilitate development of artery drug

Houston-based AngioSoma Inc. entered into a partially binding letter of intent to acquire Diabetes Relief LLC.

Financial terms of the proposed transaction were not disclosed.

Diabetes Relief, also headquartered in Houston, licenses medical facilities to provide patients with personalized treatments for metabolic disorders, specializing in diabetes. The facilities use patented protocols, processes and intellectual property, according to AngioSoma.

AngioSoma expects Diabetes Relief to book gross revenues of about $2.4 million for 2018, up from about $1.9 million in 2017 and $213,434 in 2015.

The biotechnology company expects Diabetes Relief to see substantial revenue growth while facilitating clinical trials to support the U.S. Food and Drug Administration's approval of Liprostin. Liprostin is meant to treat peripheral artery disease — the narrowing of arteries serving the limbs.